AIP
CRMD icon

Ahrens Investment Partners’s CorMedix CRMD Stock Holding History

Ahrens Investment Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,000
Closed -$2K – 170
2018
Q1 		$2K Hold
2,000
– – ﹤0.01% 163
2017
Q4 		$5K Hold
2,000
– – ﹤0.01% 163
2017
Q3 		$5K Hold
2,000
– – ﹤0.01% 160
2017
Q2 		$4K Hold
2,000
– – ﹤0.01% 168
2017
Q1 		$16K Buy
2,000
+1,800
+900% +$17.2K 0.01% 156
2016
Q4 		$15K Buy
+200
New +$2.02K 0.01% 143

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
PD
Planning Directions Glen Mills, Pennsylvania $198M AUM 11.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Ahrens Investment Partners's CRMD Position: Q2 2018 in Review

Ahrens Investment Partners sold out of CorMedix (CRMD) in Q2 2018, closing a stake of 2,000 shares — an estimated $2K sold.

Ahrens Investment Partners first reported a position in CRMD in Q4 2016 and held it in 6 quarters. The position peaked at $16K in Q1 2017. 34 funds tracked by Wall St. Rank hold CRMD as of Q2 2018.

  • Ahrens Investment Partners reported no remaining CorMedix position as of Q2 2018 after selling out during the quarter.
  • Ahrens Investment Partners sold 2,000 CorMedix shares in Q2 2018, an estimated $2K.
  • Ahrens Investment Partners first reported a position in CorMedix in Q4 2016 and held it in 6 quarters.
  • Ahrens Investment Partners's CorMedix position peaked at $16K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held CorMedix as of Q2 2018.

Based on Ahrens Investment Partners's 13F filing for Q2 2018, filed 10 Aug 2018.